SynergenX Health review

What it is

SynergenX Health is a hormone and weight-loss clinic chain operating 64 locations across Texas, Illinois, Tennessee, Colorado, Arkansas, Indiana, Missouri, North Carolina, Ohio and Oklahoma, formed through a merged network with Low T Center. Its core business is hormone optimisation, including testosterone replacement therapy, with a telehealth GLP-1 weight-loss program built on compounded semaglutide alongside it. Its site names Sermorelin Peptide Therapy in its service navigation and a PT-141 peptide under its women's services, and offers comprehensive hormone testing with an out-of-pocket option for new patients.

How it works

Hybrid, and weighted heavily toward in-person care. The clinic network is the substance of the business — 64 locations means a physical bench, real appointment slots and a hormone practice that predates the telehealth boom, which is a different risk profile from a platform founded last year. Its telehealth arm, though, is narrow: the online sign-up currently offers Texas as the only state, with more described as rolling out and no timeline published. For a national audience that makes this primarily a directory entry rather than a service you can start today. The GLP-1 program, which is the part of the site with published detail, runs on a $100 initial telehealth visit and $40 follow-ups every one to three months, with medication and refrigerated shipping stated as covered. What is not published anywhere is the peptide side of the operation: no price for sermorelin or PT-141, no dosing, no protocol detail, and no statement of whether labs are involved. Nor does the site name a compounding pharmacy, an accreditation, or a medical director, which for a chain of this size is a surprising omission rather than a typical one.

Pricing transparency

Absent for the molecules this board is about, and we will not manufacture one. Sermorelin Peptide Therapy and the PT-141 peptide are both named as services and neither carries a published figure anywhere on the site. The number the site does publish — compounded semaglutide starting as low as $150 for one month of treatment, with a $100 initial telehealth visit and $40 follow-ups — is a GLP-1 price, and substituting it for a peptide price would be exactly the error this roundup exists to avoid. So no floor appears on its card. Two things to ask if you call: what a sermorelin protocol costs at your nearest clinic, since a chain with 64 locations may not price identically across ten states, and whether hormone lab work is billed separately from the therapy. Its published hormone testing offer — an insurance copay or $99 out of pocket for new patients — suggests labs are a separate line item rather than a bundled one.

Branded vs compounded

Compounded where compounded, and not FDA-approved. Prescription required only if a licensed provider finds it appropriate. No compounding pharmacy is named, no accreditation is displayed and no medical director is published, so the supply chain behind an injectable here is less traceable than the clinic network in front of it. Compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, the two named peptides are quite different propositions. Sermorelin is a GHRH analogue that stimulates your own pituitary rather than supplying growth hormone from outside, preserving a feedback loop that exogenous growth hormone overrides — a real, well-characterised mechanism whose long-term human outcome data stays thin past short-term IGF-1 movement. PT-141, bremelanotide, is the more interesting case: it is an FDA-approved drug, but for one narrow indication only, generalised hypoactive sexual desire disorder in premenopausal women, so a compounded version prescribed outside that population is off-label use of an approved molecule rather than an unapproved compound. Its testosterone line has a large randomised safety base and requires ongoing haematocrit, PSA and testosterone monitoring, which a clinic-based practice is structurally better placed to deliver than a shipping service. Individual results vary.

Pros and watch-outs

The evidence behind what SynergenX Health prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• PT-141 (bremelanotide): the evidence on a research-popular peptide that is actually FDA-approved

  Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women, with phase-3 trial evidence. A straight read of what's proven — and where off-label use goes beyond it.

• TRT: what testosterone therapy is actually proven to do

  An FDA-approved therapy for diagnosed hypogonadism — with real but moderate benefits (sexual function, mood; not vitality), cardiovascular non-inferiority in TRAVERSE, and a real fertility trade-off.

How SynergenX Health compares

A few alternatives worth a look, depending on what you’re optimizing for.

• RERegenCen

  Patients in Michigan, Florida or the South Carolina Lowcountry who want NAD⁺ inside supervised hormone care

  See RegenCen →
• RHRylo Health

  NAD⁺ buyers who want a named pharmacy and the month-to-month rate stated up front

  See Rylo Health →
• RXRxPepsDirect

  NAD⁺ buyers who want the milligrams stated so they can compare cost per dose

  See RxPepsDirect →